Adaptive Phage gets $10M from DoD for antibacterial phage therapies
Source: External source
The company is developing phage-based therapies designed to target specific bacteria strains, as contrasted with antibiotics, which target multiple types of bacteria.
Posted January 8, 2020
About TEDCO
TEDCO, the Maryland Technology Development Corporation, enhances economic empowerment growth through the fostering of an inclusive entrepreneurial innovation ecosystem. TEDCO identifies, invests in, and helps grow technology and life science-based companies in Maryland. Learn more at www.tedcomd.com.
Media Contacts
Tammi Thomas, President, TEDCO, tthomas@tedcomd.com
Rachael Kalinyak, Associate Director, Marketing & Communications, TEDCO, rkalinyak@tedcomd.com